搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Burkholderia sp. 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (ispE) CSB-YP658610BAAK
CSB-EP658610BAAK
CSB-BP658610BAAK
CSB-MP658610BAAK
CSB-EP658610BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. NADPH-dependent 7-cyano-7-deazaguanine reductase (queF) CSB-YP658611BAAK
CSB-EP658611BAAK
CSB-BP658611BAAK
CSB-MP658611BAAK
CSB-EP658611BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. Protein RecA (recA) CSB-YP658612BAAK
CSB-EP658612BAAK
CSB-BP658612BAAK
CSB-MP658612BAAK
CSB-EP658612BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. UDP-N-acetylenolpyruvoylglucosamine reductase (murB) CSB-YP658613BAAK
CSB-EP658613BAAK
CSB-BP658613BAAK
CSB-MP658613BAAK
CSB-EP658613BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. ATP-dependent Clp protease adapter protein ClpS (clpS) CSB-YP658614BAAK
CSB-EP658614BAAK
CSB-BP658614BAAK
CSB-MP658614BAAK
CSB-EP658614BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. Probable cytosol aminopeptidase (pepA), partial CSB-YP658615BAAK
CSB-EP658615BAAK
CSB-BP658615BAAK
CSB-MP658615BAAK
CSB-EP658615BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. Chaperone protein htpG (htpG), partial CSB-YP658616BAAK
CSB-EP658616BAAK
CSB-BP658616BAAK
CSB-MP658616BAAK
CSB-EP658616BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. Uracil phosphoribosyltransferase (upp) CSB-YP658617BAAK
CSB-EP658617BAAK
CSB-BP658617BAAK
CSB-MP658617BAAK
CSB-EP658617BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. Polyribonucleotide nucleotidyltransferase (pnp), partial CSB-YP658618BAAK
CSB-EP658618BAAK
CSB-BP658618BAAK
CSB-MP658618BAAK
CSB-EP658618BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. Sulfate adenylyltransferase subunit 2 (cysD) CSB-YP658619BAAK
CSB-EP658619BAAK
CSB-BP658619BAAK
CSB-MP658619BAAK
CSB-EP658619BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. DNA mismatch repair protein MutS (mutS), partial CSB-YP658620BAAK
CSB-EP658620BAAK
CSB-BP658620BAAK
CSB-MP658620BAAK
CSB-EP658620BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. [Protein-PII] uridylyltransferase (glnD), partial CSB-YP658621BAAK
CSB-EP658621BAAK
CSB-BP658621BAAK
CSB-MP658621BAAK
CSB-EP658621BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. UDP-3-O-acylglucosamine N-acyltransferase (lpxD) CSB-YP658622BAAK
CSB-EP658622BAAK
CSB-BP658622BAAK
CSB-MP658622BAAK
CSB-EP658622BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. Large-conductance mechanosensitive channel (mscL), partial CSB-YP658623BAAK1
CSB-EP658623BAAK1
CSB-BP658623BAAK1
CSB-MP658623BAAK1
CSB-EP658623BAAK1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. UPF0061 protein Bcep18194_A5209 (Bcep18194_A5209), partial CSB-YP658624BAAK
CSB-EP658624BAAK
CSB-BP658624BAAK
CSB-MP658624BAAK
CSB-EP658624BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. UPF0133 protein Bcep18194_A5127 (Bcep18194_A5127) CSB-YP658625BAAK
CSB-EP658625BAAK
CSB-BP658625BAAK
CSB-MP658625BAAK
CSB-EP658625BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. GTPase Der (der) CSB-YP658626BAAK
CSB-EP658626BAAK
CSB-BP658626BAAK
CSB-MP658626BAAK
CSB-EP658626BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. LexA repressor (lexA) CSB-YP658627BAAK
CSB-EP658627BAAK
CSB-BP658627BAAK
CSB-MP658627BAAK
CSB-EP658627BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. Ribose import ATP-binding protein RbsA 1 (rbsA1), partial CSB-YP658628BAAK
CSB-EP658628BAAK
CSB-BP658628BAAK
CSB-MP658628BAAK
CSB-EP658628BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia sp. 50S ribosomal protein L35 (rpmI) CSB-YP658629BAAK
CSB-EP658629BAAK
CSB-BP658629BAAK
CSB-MP658629BAAK
CSB-EP658629BAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>